department

Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access

therapeutic area

Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease

location & type

Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →

when

Latest
Archive

by source

All Sources
Sources Page

by activity

Most Active
Biggest Pipelines
Recently Active

hiring

Companies Hiring Now
Big Pharma Roles
All Companies →

Drugs & Pipeline

intelligence

Drugs
Patent Cliff

research

Publications
Topics

window

Next 90 Days
All (incl. Past)

by type

PDUFAs
Approvals
Earnings
Readouts

Sign In Subscribe

pharmadog

fetch the data · sniff the signal

Discover

Calendar
Drugs
Companies
News

Hubs

Topics
Jobs
Patent cliff
Publications

Tools

Compare
Search
Bookmarks

Trust

About
Sources
Contact

Legal

Privacy
Terms
Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

home
jobs
news
cal
search

Invega Sustenna · pharmadog

pharmadog
drugs
Invega Sustenna

drug

patient view →

paliperidone palmitate LA

Marketedupdated 2mo ago

by Johnson & Johnson Innovative Medicine

Approved

community read0 votes

indications

investigational

Schizophrenia

all catalysts(0)

nothing on the calendar yet

News(0)

no news has mentioned this drug yet

brand

Invega Sustenna

generic

paliperidone palmitate

indication

Schizoaffective Disorder

phase

marketed

Data sources

ClinicalTrials.gov

last refreshed 2h ago

Found something off?

🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

comments(0)

5-min edit window · permanent after that

sign in to leave a comment · permanent archive after 5 minutes

no comments yet — first sniff?

Patent cliff

source: FDA Orange Book

first barrier falls

Jan 26, 2031

~4.6 years out

Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.

patents (29)

Nov 24, 2041method-of-use (U-3626)US 11666697
Nov 24, 2041method-of-use (U-3626)US 11666697
May 7, 2041method-of-use (U-3349)US 11304951
May 7, 2041method-of-use (U-3349)US 11304951
May 7, 2041method-of-use (U-3359)US 11324751
May 7, 2041method-of-use (U-3359)US 11324751
May 7, 2041method-of-use (U-3359)US 12208100
May 7, 2041method-of-use (U-4110)US 12208100
Sep 24, 2039method-of-use (U-3968)US 11666573
Sep 24, 2039method-of-use (U-3968)US 11666573
Sep 24, 2039method-of-use (U-3968)US 11666573
Sep 24, 2039method-of-use (U-3969)US 11666573
Sep 24, 2039method-of-use (U-3968)US 11666573
Sep 24, 2039method-of-use (U-3968)US 11666573
Oct 26, 2038method-of-use (U-3968)US 12128049
Oct 26, 2038method-of-use (U-3968)US 12128049
Oct 26, 2038method-of-use (U-3969)US 12128049
Oct 26, 2038method-of-use (U-3968)US 12128049
Oct 26, 2038method-of-use (U-3968)US 12128049
Oct 26, 2038method-of-use (U-3968)US 12128049
Apr 5, 2036method-of-use (U-2457)US 10143693
Apr 5, 2036method-of-use (U-2458)US 10143693
Apr 5, 2036method-of-use (U-2457)US 10143693
Apr 5, 2036method-of-use (U-2457)US 10143693
Jan 26, 2031method-of-use (U-2757)US 94399064.6y
Jan 26, 2031method-of-use (U-2758)US 94399064.6y
Jan 26, 2031method-of-use (U-2757)US 94399064.6y
Jan 26, 2031method-of-use (U-2758)US 94399064.6y
Jan 26, 2031method-of-use (U-2757)US 94399064.6y

Trials studying paliperidone palmitate LA

N/AA Bioequivalence Study of PP3M in Patients With Schizophreniarecruitingn=260
N/ABioequivalence Study of Long-Acting Paliperidone Palmitate in Patients With Schizophreniacompletedn=256
phase3A Study to Compare Disease Progression and Modification Following Treatment With Paliperidone Palmitate Long-Acting Injection or Oral Antipsychotics in Participant's With Recent-onset Schizophrenia or Schizophreniformcompletedn=337
phase4A Study to Assess the Treatment of Schizophrenia With Paliperidone Palmitate in Rwandan Healthcare Settingscompletedn=93
—A Study to Analyze the Impact of Treatment With Paliperidone Palmitate on Clinical Outcomes and Hospital Resource Utilization in Adult Participants With Schizophrenia in Portugalcompletedn=55
—A Survey to Collect Treatment Experience Feedback From Patients, Physicians, Nurses and Carers After Switching to Paliperidone Palmitate 3-monthlycompletedn=225
phase4A Study to Evaluate the Ability of Conducting a Study of Oral Risperidone Followed by Paliperidone Palmitate in Rwandan Healthcare Facilitiescompletedn=34
phase3A Study of Transition to the Paliperidone Palmitate 3-Month Formulation In Participants With Schizophrenia Previously Stabilized on the Paliperidone Palmitate 1-Month Formulationcompletedn=306

more trials →